News

Mepolizumab Lessens Exacerbations, Improves Quality of Life

Treatment with mepolizumab, an antibody designed to lower the levels of eosinophils — immune cells linked with worse chronic obstructive pulmonary disease (COPD) — was found to reduce the annual rate of exacerbations and improve health-related quality of life in people with eosinophil-associated COPD. The findings, from a meta-analysis…

Certain Lung Cells Seen to Reverse Emphysema in Preclinical Study

Injecting mice with healthy lung endothelial cells — specialized cells lining the inside of blood vessels — prevented, and in some cases reversed, lung damage associated with emphysema, a severe form of chronic obstructive pulmonary disease (COPD), in a recent study. The study, “Reversal of emphysema…

Zephyr Valve Led to Sustained Benefits in Homogeneous Emphysema

The Zephyr Endobronchial Valve leads to sustained and significant improvements in lung function, exercise capacity, and quality of life in people with homogeneous emphysema, a severe form of chronic obstructive pulmonary disease (COPD), according to one-year data from the IMPACT clinical study. “This is very important data because…

Protein Implicated in Emphysema May Be Potential Therapeutic Target

Mice lacking a protein called FCHSD1 were protected from developing emphysema, a severe form of chronic obstructive pulmonary disease (COPD), according to data from a recent study. Based on these observations, researchers say this protein could serve as a future therapeutic target for COPD. “Our findings may also lead…

Platelet-based Therapy May Slow Lung Function Decline

Treatment with PRP-PC, an investigational platelet-based cellular therapy, may slow the decline in lung function typically experienced by people with chronic obstructive pulmonary disease (COPD), a new study with real-world data indicates. With this therapy, being developed by H-CYTE, a person’s own blood is treated in the lab…